Peginterferon alfa-2b drug data and news

Peginterferon alfa-2b drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name

Peginterferon alfa-2b

Brand Names/Synonyms

Interferon alpha-2 precursor;Interferon alpha-A;LeIF A; PEG-Intron

Indication

For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma

Sponsored links

Description

PEGylated interferon alpha, total length is 165 amino acids. PEG-Intron is a covalent conjugate of recombinant alfa interferon with monomethoxy polyethylene glycol (PEG). The molecular weight of the PEG portion of the molecule is 12,000 daltons. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. It has a single substitution where K23 is switched to R23

Pharmacology

Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.

Mechanism Of Action

Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.

Peginterferon alfa-2b News
(When available)

MIGENIX Receives Approval for MX-3253 Phase II Combination Viral ... 16 May 2006
The study is designed to demonstrate improved antiviral activity when celgosivir is used in combination with peginterferon alfa-2b, with or without ribavirin ... - Yahoo! News (press release)

EU Label Change for Intron A (Interferon Alfa-2b) Incorporates ... Apr 26, 2006
Schering-Plough also markets a longer-acting, once-weekly pegylated version of interferon alfa-2b called PEG-Intron (peginterferon alfa-2b), for use as ... - DG News

EU Label Change for INTRON(R) A (interferon alfa-2b) Incorporates ... Apr 25, 2006
Schering-Plough also markets a longer-acting, once-weekly pegylated version of interferon alfa-2b called PEGINTRON (peginterferon alfa-2b), for use as ... - Finanzen.net,

MIGENIX to Present at Several Upcoming Investor and Scientific ... May 2, 2006
I inhibitor for the treatment of chronic hepatitis C virus (HCV) infections currently enrolling patients in combination with peginterferon alfa-2b; with and ... - Yahoo! News (press release)

WIN-R Study Demonstrates Efficacy of Shorter PEG-Intron and ... Apr 28, 2006
...patients infected with hepatitis C virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-Intron(R) (peginterferon alfa-2b) in combination ... - DG News

Schering-Plough's shorter dose hepatitis regimen shows promise May 2, 2006
..."These findings are important because they confirm the effectiveness of a shorter course of peginterferon alfa-2b and ribavirin combination therapy for ... - Pharmaceutical Business Review

Schering-Plough Advances Development of Hepatitis Capsules Apr 21, 2006
SCH 503034 is being evaluated in a large phase II study in combination with peg-intron (peginterferon alfa-2b) for the treatment of patients chronically ... - International News Service,

Schering-Plough Provides Update on Oral HCV Protease Inhibitor SCH ... Apr 19, 2006
SCH 503034 is being evaluated in a large Phase II study in combination with PEG-INTRON® (peginterferon alfa-2b) for the treatment of patients chronically ... - Yahoo! News (press release)

Schering-Plough Provides Phase II Hepatitis C Drug Update Apr 20, 2006
SCH 503034 is being evaluated in a Phase II study in combination with PEG-INTRON, or peginterferon alfa-2b, for the treatment of patients chronically infected ... - Therapeutics Daily (subscription) (press release),

Dosage Forms

POWDER FOR SOLUTION

Drug_Category

Antiviral Agents; Immunomodulatory Agents; Antineoplastic Agents; interferons (08:18.20)

Absorption

Not Available

Interactions

Not Available

Toxicity

Not Available

Organisms Affected

Not Available

Chemical IUPAC Name

PEGylated human interferon alpha 2b

Chemical Formula

C860H1353N229O255S9

Molecular Weight

19269.1

Smiles String

Not Available

Melting Point

61 oC (Beldarrain, A. et al., Biochemistry 38:7865-7873 (1999)) Davis JM, Narachi MA, Levine HL, Alton NK, Arakawa T. Conformation and stability of two recombinant human interferon-alpha analogs. Int J Pept Protein Res. 1987 Jun;29(6):685-91.

Water Solubility

Not Available

State

Transparent, slightly viscous, aqueous liquid

LogP/Hphobicity

-0.339

Isoelectric Point

5.99

Biotransformation

Not Available

Half Life

22-60 hrs

Protein Binding [%]

Not Available

RxList Link

RXlist

Sponsored links

Drug Reference

http://www.rxlist.com/cgi/generic2/peginterferon.htm

Drug Type

Approved Drug

Accession No

BIOD00048

CAS Registry Number

99210-65-8

KEGG Compound ID

Not Available

PubChem ID

Not Available

PharmGKB ID

PA10153

SwissProt ID

IFNA2_HUMAN (P01563)

GenBank ID

J00207

Drug ID Number [DIN]

2242966